Thrombosis in multiple myeloma: mechanisms, risk assessment and management

AbstractMultiple myeloma (MM) is associated with an increased risk of venous and arterial thrombosis. Pathophysiologic mechanisms include patient, disease and treatment related factors. Risk assessment models have been developed to determine whichpatients are at highest thrombotic risk and pursuant to this, risk adapted thrombosis prophylaxis has been suggested. Areas in which further basic and clinical research is imperative include the molecular and cellular mechanisms of thrombosis in myeloma, the inclusion of relevant biomarkers in risk assessment scores and controlled clinical trials of VTE prophylaxis and treatment using direct oral anticoagulants.Keywords: Venous thromboembolismarterial thrombosisrisk assessmentprophylaxis Additional informationFundingThe author(s) reported there is no funding associated with the work featured in this article.